Rafijul Bari

Rafijul Bari has extensive experience in the field of cancer immunotherapy and research. Rafijul is currently working as the Director of Research and Early Development at Celularity Inc., where they lead the cancer immunotherapy program and is responsible for strategic planning and the management of preclinical studies. Prior to this role, Rafijul served as a Manager at Lentigen/Miltenyi Biotec, where they were the biology lead for cancer immunotherapy and played a key role in target validation and preclinical studies. Rafijul has also held roles as a Principal Investigator at KK Women's & Children's Hospital, a Senior Scientist at Miltenyi Biotec, and a Staff Scientist at St. Jude Children's Research Hospital. Rafijul's expertise in the field is evident from their extensive research experience and contributions to the development of cell-based therapeutic programs.

Rafijul Bari obtained a Master's Degree in Molecular Biology from Vrije Universiteit Brussel (VUB), Belgium in 2000. Rafijul then went on to pursue a PhD in Genetics and Molecular Biology at RWTH Aachen University from 2000 to 2004.